Lung Cancer, Non-small Cell Lung Cancer NSCLC, Small Cell Lung Cancer SCLC
Conditions
Brief summary
The purpose of the study is to document real-world pattern of care, outcomes and health resource use for participants diagnosed with and receiving treatment for advanced Non-small cell lung cancer (NSCLC) and extensive disease Small cell lung cancer (SCLC) in China.
Interventions
None listed
Sponsors
Bristol-Myers Squibb
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed advanced NSCLC (IIIB/IV) and extensive disease SCLC with pathology/cytology record between 1-Dec-2013 and 30-Nov-2014 * Received inpatient treatment more than twice (inclusive) at a selected site. For hospitals with outpatient records, patients receiving oral TKI therapy and routinely (more than twice a year) followed up outpatient will be included although no inpatient records. For hospitals with outpatient chemotherapy center, patients will be include if they were prescribed with chemotherapy and routinely (more than twice a year, inclusive) followed up outpatient in the hospital * 18 years of age or older at initial diagnosis of IIIB/IV NSCLC and extensive disease SCLC
Exclusion criteria
* Patients who have participated in or are attending clinical trials receiving active LC therapy * Unknown initial diagnosis time and initial treatment time. * For hospitals without outpatient chemo therapy center, patients who were prescribed with chemo therapy but with no inpatient records will be excluded * Patients who received inpatient therapy for one time and were not routinely (more than twice a year, inclusive) followed up outpatient will be excluded Other protocol defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Distribution of subsequent therapy completion rate | Approximately 36 months | Completion of more than 4 cycles |
| Distribution of first-line regimens | Approximately 36 months | All chemotherapy, radiation and/or biologic drugs given to a patient during the first 28 days after initiation of treatment |
| Proportion of participants receiving fourth-line systemic therapy | Approximately 36 months | Proportion of patients receiving fourth-line systemic anti-cancer treatment (chemotherapy, biologic/targeted therapy) |
| Proportion of participants receiving first-line systemic therapy | Approximately 36 months | Proportion of patients receiving first-line systemic anti-cancer treatment (chemotherapy, biologic/targeted therapy) |
| Proportion of participants receiving second-line systemic therapy | Approximately 36 months | Proportion of patients receiving second-line systemic anti-cancer treatment (chemotherapy, biologic/targeted therapy) |
| Proportion of participants receiving third-line systemic therapy | Approximately 36 months | Proportion of patients receiving third-line systemic anti-cancer treatment (chemotherapy, biologic/targeted therapy) |
| Distribution of subsequent regimens | Approximately 36 months | All chemotherapy, radiation and/or biologic drugs given to a patient following first-line regimen |
| Distribution of first-line treatment duration | Approximately 36 months | Calculated by the difference between the treatment start date of the first observed drug in the regimen and the last observed date of the regimen |
| Distribution of subsequent treatment duration | Approximately 36 months | Calculated by the difference between the treatment start date of the first observed drug in the regimen and the last observed date of the regimen |
| Distribution of first-line therapy completion rate | Approximately 36 months | Completion of more than 4 cycles |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Distribution of patient demographic data | At baseline | — |
| Distribution of disease characteristic data | At baseline | — |
| Distribution of Overall Survival from first observed diagnosis to death | At baseline | — |
| Distribution of Overall Survival from the initiation of first-line systemic anti-cancer therapy to death | At baseline | — |
| Distribution of Overall Survival from the initiation of second-line systemic anti-cancer therapy to death | At baseline | — |
| Distribution of Overall Survival from the initiation of third-line systemic anti-cancer therapy to death | At baseline | — |
| Distribution of Overall Survival from the initiation of fourth-line systemic anti-cancer therapy to death | At baseline | — |
| Distribution of other cancer-directed therapies | Approximately 36 months | Distribution of other cancer-directed therapies including surgery and radiation as well as supportive care |
| Distribution of Interval of Therapy | Up to 36 months | — |
| Distribution of Lung Cancer related direct health care costs | Up to 36 months | — |
Countries
China
Outcome results
None listed